Gaudium IVF and Women Health Ltd Q4 FY2026 Concall Summary

Key Takeaways

• IPO proceeds funding a disciplined hub rollout: 19 new IVF hubs planned, with 10 in FY27 and the first three opening within months, all funded by the ₹165 crore IPO and internal accruals.
• AI integration is now live, not a pilot: SiD and ERICA were formally integrated on 1 April 2026, with early results showing an almost 8% increase in first-attempt success rates, a metric that directly drives revenue and reputation.
• Trade receivables are a known friction, with a fix underway: The company doubled the initial patient payment and added a penalty for delayed transfers, measures management says will reduce receivables significantly by the end of this quarter.
• The model is built to replicate: SOPs cover everything from embryology to housekeeping, and all centres deliver results within plus or minus 1% of each other, a claim that underpins the hub-and-spoke scaling thesis.
• What to watch next quarter: Whether the three new hubs open on schedule, whether trade receivables actually decline as promised, and any detail on the tax litigation that management declined to discuss.

The Clinician-Led Moat

• Founder as differentiator: The company argues its deepest competitive advantage is that it was built from real-world clinical practice, with the founder still shaping strategy even after stepping out of daily operations in 2019.
• SOP depth is the scaling engine: Standard operating procedures cover everything from clinical embryology to the mop material and cleaning solution used in centres, which is how all centres deliver results within a 1% band of each other.
• Training as a control point: Before posting to any new centre, clinicians, embryologists and chief nursing staff undergo compulsory in-house training at Delhi headquarters with exit exams set by the three national chiefs.
• Retention backs the claim: The national chief embryologist has been with the company for about 12 of its 16 years, and management attributes low attrition to professional growth, annual increments and professional satisfaction.

Manika Khanna: "Deep clinical leadership is not just an advantage; it is the foundation of long-term trust, and, in fact, this is our biggest sustainable differentiator in this industry because the leader is a clinician."

Hub-and-Spoke Expansion

• IPO-funded rollout is front-loaded: 19 new IVF hubs are planned under the IPO use of proceeds, with 10 in FY27, 8 in FY28 and 1 in FY29, plus nine new spokes in the next couple of months.
• First hubs are imminent: Three hubs are expected operational within the next couple of months, including a large hub in South Delhi to be inaugurated in the coming month, plus two others in Nagpur and Gurgaon.
• Asset-light principle stays: Management is confident it can maintain high growth in both profit and revenue because the asset-light hub-and-spoke model refined over 16 years remains unchanged, with FY27 capex expected at only ₹25 crore.
• International spokes are a small bet with upside: Three international spokes are opening this quarter in Paris, Nigeria and Sydney, and management says the international patient contribution is "only bound to increase" while targeting medical tourism "very aggressively."
• ROCE ambition: Management expects 35% to 40% ROCE in the next 3 to 5 years when the new hubs are fully functional.

Manika Khanna: "We have created such a solid structure that now the building's basement is ready, it won't take time to build the floors above."

AI Integration & Embryology Productivity

• Two AI systems went live on 1 April 2026: SiD handles sperm selection and ERICA ranks embryos, both developed in partnership with UK-headquartered IVF 2.0, making Gaudium the first IVF chain in India to formally integrate AI-led embryology into routine clinical practice.
• Early results are material: The addition of SiD and ERICA has produced an almost 8% increase in results at the first attempt, a metric that directly improves the clinic's success-rate positioning and patient conversion.
• Productivity mechanism: AI tools reduce time per case because decisions happen in milliseconds, and faster procedures mean the embryo, egg or sperm spend less time outside the incubator, which yields higher results.
• Embryologist throughput: The company achieves 120 pickups per embryologist, which management attributes to being "hardworking people" who "optimize our results very well," with AI now adding a further efficiency layer.

Success Rates & Quality Positioning

• First-cycle success rate of 58% is positioned as "at par with global standards," with management noting that the American Society for Reproductive Medicine considers 40% to be a very good success rate.
• Cumulative pregnancy rate of 85% means 8.5 out of 10 couples leave pregnant, a framing that doubles as a patient-acquisition message.
• Pricing philosophy is anchored to outcomes: Management explicitly rejects price competition, stating the product is human life and cannot be treated like a consumer durable.

Manika Khanna: "We are creating human life. So, it's not a fridge or a television. So, we can't mess with life."

Trade Receivables & Affordability

• Receivables have two sources: Medical reasons under the freeze-all policy, where diabetic or other patients need delayed embryo transfer of up to 5 to 6 months, and financial reasons where patients cannot pay all at once. Management says both categories are "almost the same" in size.
• Three corrective measures are in place: The initial payment for new patients was doubled from ₹40,000 to ₹80,000, an additional charge of ₹40,000 was imposed on patients who do not come for transfer within one year, and the calling team is now actively educating patients to speed up transfers.
• Zero bad debt so far is the offsetting fact, and management says trade receivables will "reduce significantly" by the end of this quarter.
• Affordability push continues separately: A Pan-India tie-up with HDFC Bank helps patients with financing, and a credit scheme lets patients complete egg retrieval at a basic price, freeze the embryo, and take 5 to 6 months to pay before transfer.

Business Mix & Capital Allocation

• IVF is the engine and will stay that way: IVF treatment contributed about 79% of revenue in FY25 and is expected to expand further as the company scales.
• Pharmacy is a support function, not a growth vertical: The pharmacy segment exists only to ensure consistent availability of specialized medications and consumables for IVF patients and is not intended to scale independently.
• Egg freezing is the next growth area: Management calls egg freezing "reproductive freedom" and describes it as a huge business area for growth.
• Capital allocation follows the core: Management attention, capital allocation and growth investments will be directed predominantly toward IVF treatments and expansion of the hub-and-spoke network.

Manika Khanna: "The more babies we make, the more business we make, and the more business we invite in the future."

Guidance & Commitments

Key Metrics